The immunophenotype of acute promyelocytic leukemia (APL)

An ECOG study

Elisabeth M. Paietta, Janet Andersen, Robert Gallagher, John Bennett, Jorge Yunis, Peter Cassileth, Jacob Rowe, Peter H. Wiernik

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

In 452 adult patients with de novo acute myeloid leukemia (AML), a series of 22 monoclonal antibodies was used to identify immunophenotypic characteristics of acute promyelocytic leukemia (APL) as compared to other AMLs (groups FAB M1/M2 and M4/M5). Only those patients with FAB M3 cytology were included in the analysis for which APL was confirmed by the presence of the t(15;17) cytogenetic aberration and the detection of the PML/RARα gene fusion transcript by PCR amplification (35 cases). Significantly fewer APL blast cells were positive for the stem cell antigen, CD34 (p = 0.0001) as well as for HLA-DR (p < 0.0001). With respect to myeloid antigens, APLs less frequently expressed the myelomonocytic antigens, CD11b (p = 0.0001) and CD14 (p = 0.0013), whereas expression of CD33, a pan-myeloid marker, was more frequent in APL (p = 0.0001). CD15, the X-hapten carbohydrate structure (lacto-N-fucopentaose-III), typically expressed at the maturation stage of normal promyelocytes, was found to be sialylated on APL blasts as recognized by differential binding of the anti-CD15 antibodies, VIM-D5 (non-sialylated CD15) and VEP-9 (sialylated CD15). Expression of the T-cell associated CD7 antigen was rarer on APL than non-APL cells (p = 0.0001), as was that of the multidrug resistance P-glycoprotein (p = 0.0038). Marginal correlations existed between antigen profile (particularly CD2) and the type of PML/RARα transcripts. In addition to its unique genotypic features, these data establish APL as a distinct immunophenotypic entity.

Original languageEnglish (US)
Pages (from-to)1108-1112
Number of pages5
JournalLeukemia
Volume8
Issue number7
StatePublished - Jul 1994

Fingerprint

Acute Promyelocytic Leukemia
CD7 Antigens
CD11b Antigens
CD34 Antigens
CD15 Antigens
Antigens
Granulocyte Precursor Cells
Gene Fusion
Multiple Drug Resistance
P-Glycoprotein
HLA-DR Antigens
Acute Myeloid Leukemia
Chromosome Aberrations
Cell Biology
Anti-Idiotypic Antibodies
Leukemia
Stem Cells
Monoclonal Antibodies
Carbohydrates
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Paietta, E. M., Andersen, J., Gallagher, R., Bennett, J., Yunis, J., Cassileth, P., ... Wiernik, P. H. (1994). The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study. Leukemia, 8(7), 1108-1112.

The immunophenotype of acute promyelocytic leukemia (APL) : An ECOG study. / Paietta, Elisabeth M.; Andersen, Janet; Gallagher, Robert; Bennett, John; Yunis, Jorge; Cassileth, Peter; Rowe, Jacob; Wiernik, Peter H.

In: Leukemia, Vol. 8, No. 7, 07.1994, p. 1108-1112.

Research output: Contribution to journalArticle

Paietta, EM, Andersen, J, Gallagher, R, Bennett, J, Yunis, J, Cassileth, P, Rowe, J & Wiernik, PH 1994, 'The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study', Leukemia, vol. 8, no. 7, pp. 1108-1112.
Paietta EM, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P et al. The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study. Leukemia. 1994 Jul;8(7):1108-1112.
Paietta, Elisabeth M. ; Andersen, Janet ; Gallagher, Robert ; Bennett, John ; Yunis, Jorge ; Cassileth, Peter ; Rowe, Jacob ; Wiernik, Peter H. / The immunophenotype of acute promyelocytic leukemia (APL) : An ECOG study. In: Leukemia. 1994 ; Vol. 8, No. 7. pp. 1108-1112.
@article{88f833eb6b92465b8d48351a40e66d05,
title = "The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study",
abstract = "In 452 adult patients with de novo acute myeloid leukemia (AML), a series of 22 monoclonal antibodies was used to identify immunophenotypic characteristics of acute promyelocytic leukemia (APL) as compared to other AMLs (groups FAB M1/M2 and M4/M5). Only those patients with FAB M3 cytology were included in the analysis for which APL was confirmed by the presence of the t(15;17) cytogenetic aberration and the detection of the PML/RARα gene fusion transcript by PCR amplification (35 cases). Significantly fewer APL blast cells were positive for the stem cell antigen, CD34 (p = 0.0001) as well as for HLA-DR (p < 0.0001). With respect to myeloid antigens, APLs less frequently expressed the myelomonocytic antigens, CD11b (p = 0.0001) and CD14 (p = 0.0013), whereas expression of CD33, a pan-myeloid marker, was more frequent in APL (p = 0.0001). CD15, the X-hapten carbohydrate structure (lacto-N-fucopentaose-III), typically expressed at the maturation stage of normal promyelocytes, was found to be sialylated on APL blasts as recognized by differential binding of the anti-CD15 antibodies, VIM-D5 (non-sialylated CD15) and VEP-9 (sialylated CD15). Expression of the T-cell associated CD7 antigen was rarer on APL than non-APL cells (p = 0.0001), as was that of the multidrug resistance P-glycoprotein (p = 0.0038). Marginal correlations existed between antigen profile (particularly CD2) and the type of PML/RARα transcripts. In addition to its unique genotypic features, these data establish APL as a distinct immunophenotypic entity.",
author = "Paietta, {Elisabeth M.} and Janet Andersen and Robert Gallagher and John Bennett and Jorge Yunis and Peter Cassileth and Jacob Rowe and Wiernik, {Peter H.}",
year = "1994",
month = "7",
language = "English (US)",
volume = "8",
pages = "1108--1112",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - The immunophenotype of acute promyelocytic leukemia (APL)

T2 - An ECOG study

AU - Paietta, Elisabeth M.

AU - Andersen, Janet

AU - Gallagher, Robert

AU - Bennett, John

AU - Yunis, Jorge

AU - Cassileth, Peter

AU - Rowe, Jacob

AU - Wiernik, Peter H.

PY - 1994/7

Y1 - 1994/7

N2 - In 452 adult patients with de novo acute myeloid leukemia (AML), a series of 22 monoclonal antibodies was used to identify immunophenotypic characteristics of acute promyelocytic leukemia (APL) as compared to other AMLs (groups FAB M1/M2 and M4/M5). Only those patients with FAB M3 cytology were included in the analysis for which APL was confirmed by the presence of the t(15;17) cytogenetic aberration and the detection of the PML/RARα gene fusion transcript by PCR amplification (35 cases). Significantly fewer APL blast cells were positive for the stem cell antigen, CD34 (p = 0.0001) as well as for HLA-DR (p < 0.0001). With respect to myeloid antigens, APLs less frequently expressed the myelomonocytic antigens, CD11b (p = 0.0001) and CD14 (p = 0.0013), whereas expression of CD33, a pan-myeloid marker, was more frequent in APL (p = 0.0001). CD15, the X-hapten carbohydrate structure (lacto-N-fucopentaose-III), typically expressed at the maturation stage of normal promyelocytes, was found to be sialylated on APL blasts as recognized by differential binding of the anti-CD15 antibodies, VIM-D5 (non-sialylated CD15) and VEP-9 (sialylated CD15). Expression of the T-cell associated CD7 antigen was rarer on APL than non-APL cells (p = 0.0001), as was that of the multidrug resistance P-glycoprotein (p = 0.0038). Marginal correlations existed between antigen profile (particularly CD2) and the type of PML/RARα transcripts. In addition to its unique genotypic features, these data establish APL as a distinct immunophenotypic entity.

AB - In 452 adult patients with de novo acute myeloid leukemia (AML), a series of 22 monoclonal antibodies was used to identify immunophenotypic characteristics of acute promyelocytic leukemia (APL) as compared to other AMLs (groups FAB M1/M2 and M4/M5). Only those patients with FAB M3 cytology were included in the analysis for which APL was confirmed by the presence of the t(15;17) cytogenetic aberration and the detection of the PML/RARα gene fusion transcript by PCR amplification (35 cases). Significantly fewer APL blast cells were positive for the stem cell antigen, CD34 (p = 0.0001) as well as for HLA-DR (p < 0.0001). With respect to myeloid antigens, APLs less frequently expressed the myelomonocytic antigens, CD11b (p = 0.0001) and CD14 (p = 0.0013), whereas expression of CD33, a pan-myeloid marker, was more frequent in APL (p = 0.0001). CD15, the X-hapten carbohydrate structure (lacto-N-fucopentaose-III), typically expressed at the maturation stage of normal promyelocytes, was found to be sialylated on APL blasts as recognized by differential binding of the anti-CD15 antibodies, VIM-D5 (non-sialylated CD15) and VEP-9 (sialylated CD15). Expression of the T-cell associated CD7 antigen was rarer on APL than non-APL cells (p = 0.0001), as was that of the multidrug resistance P-glycoprotein (p = 0.0038). Marginal correlations existed between antigen profile (particularly CD2) and the type of PML/RARα transcripts. In addition to its unique genotypic features, these data establish APL as a distinct immunophenotypic entity.

UR - http://www.scopus.com/inward/record.url?scp=0028318936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028318936&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1108

EP - 1112

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -